miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges

Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the world. Although considerable progress has been made in the diagnosis, treatment and prognosis of CVD, there is still a critical need for novel diagnostic biomarkers and new therapeutic interventions to decrease the...

Full description

Saved in:

Bibliographic Details
Published in:	Acta pharmacologica Sinica Vol. 39; no. 7; pp. 1073 - 1084
Main Authors:	Zhou, Shan-shan, Jin, Jing-peng, Wang, Ji-qun, Zhang, Zhi-guo, Freedman, Jonathan H, Zheng, Yang, Cai, Lu
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-07-2018 Nature Publishing Group
Subjects:	Biomarkers Biomarkers - analysis Biomedical and Life Sciences Biomedicine Cardiovascular diseases Cardiovascular Diseases - diagnosis Cardiovascular Diseases - drug therapy Cardiovascular Diseases - genetics Cardiovascular Diseases - metabolism Diagnosis Heart diseases Humans Immunology Internal Medicine Medical Microbiology MicroRNAs - analysis MicroRNAs - genetics MicroRNAs - metabolism miRNA Morbidity Myocardial infarction Pharmacology/Toxicology Review Review Article Therapeutic applications Vaccine microRNA cardiovascular diseases therapeutic targets biomarker
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the world. Although considerable progress has been made in the diagnosis, treatment and prognosis of CVD, there is still a critical need for novel diagnostic biomarkers and new therapeutic interventions to decrease the incidence of this disease. Recently, there is increasing evidence that circulating miRNAs (miRNAs), i.e. endogenous, stable, single-stranded, short, non-coding RNAs, can be used as diagnostic biomarkers for CVD. Furthermore, miRNAs represent potential novel therapeutic targets for several cardiovascular disorders. In this review we provides an overview of the effects of several CVD; including heart failure, acute myocardial infarction, arrhythmias and pulmonary hypertension; on levels of circulating miRNAs. In addition, the use of miRNA as therapeutic targets is also discussed, as well as challenges and recommendations in their use in the diagnosis of CVD.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1671-4083 1745-7254
DOI:	10.1038/aps.2018.30